Company profile: Tocagen
1.1 - Company Overview
Company description
- Provider of biopharmaceutical gene therapy products in development for the treatment of cancer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tocagen
Sirna Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on RNA interference (RNAi) for human disease therapy, creating RNAi-based therapies to ultimately treat patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirna Therapeutics company profile →
Skyhawk Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics and RNA-targeting platforms that correct RNA expression. Offers SKYSTAR for RNA target assessment and prioritization; SKYLIBRARY of RNA-targeting compounds; SKYSEQ multiplex screening for testing multiple RNA targets; and SKYAI machine-learning tools for advancing RNA splicing modulators. Pipeline includes SKY-0515, a small molecule RNA splicing modifier for Huntington’s disease in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Skyhawk Therapeutics company profile →
Akouos
HQ: United States
Website
- Description: Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akouos company profile →
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foghorn Therapeutics company profile →
Laronde
HQ: United States
Website
- Description: Provider of an eRNA-based therapeutic platform, offering Endless RNA to program protein expression for therapeutic use; proprietary Natural NanoParticle technology to deliver biomolecules into human cells, enabling diverse administration routes and re-dosing; and AI-driven drug development using proprietary algorithms for rapid RNA medicine design.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Laronde company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tocagen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tocagen
2.2 - Growth funds investing in similar companies to Tocagen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tocagen
4.2 - Public trading comparable groups for Tocagen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →